TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Human Breastmilk in Young Children With Norovirus Infection of the Gut

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children with at least two stool samples taken at least 7 days apart that are positive for norovirus~* Child has an underlying disease or has received immunosuppressive medication or chemotherapy such that clearance of norovirus is expected to be impaired.~Exclusion Criteria:~* The presence of other pathogens causing diarrhea that have specific treatments does not preclude enrollment. However, specific treatment should be offered in addition to human milk.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donor Breastmilk (Type: EXPERIMENTAL): Donated human milk is subjected to pasteurization prior to use. Milk consumption is to be overseen by a Registered Dietician. Oral or enteral milk feeding will begin at 180 ml/day and will be advanced as quickly as tolerated to a goal of 360 ml/day for 6 weeks. If symptoms and stool tests for norovirus do not improve after 6 weeks, milk administration may continue for an additional 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study on Disposable Sterile Urinary Catheter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-80 year old patients;~* Retained catheter ≥ 7 days;~* Patients who were conscious and had good communication skills and volunteered to participate in the study.~Exclusion Criteria:~* Pregnant and lactating female patients;~* Diabetes patients;~* Patients allergic to sulfadiazine, silica gel and stainless steel;~* Urethral malformation, acute urethral injury, prostate disease, intermittent catheterization, suprapubic cystostomy and other patients who are not suitable for catheterization;~* Patients who have used urinary catheters for a long time or had catheters retained within one week;~* Patients who are participating in other clinical trials that interfere with this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- trial group (Type: EXPERIMENTAL): Patients in this group used the disposable urinary catheter
- control group (Type: ACTIVE_COMPARATOR): Patients in this group used super smooth antibacterial urinary catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Demonstrated a response (CR, CRu, or PR) on Study 114-NH-301 (Galiximab in combination with Rituximab compared with Rituximab in combination with Placebo) and then relapsed or progressed with a TTP \>=6 months. Relapsed disease is defined as documented disease progression using the International Workshop Response Criteria (IWRC).~* Bidimensionally measurable disease with at least 1 lesion \>=2.0 cm in a single dimension.~* Acceptable hematologic, hepatic, and renal function.~Key Exclusion Criteria:~* Any lymphoma therapy between Final Visit on Study 114-NH-301 and Study Day 1 of this retreatment study.~* Chronic or intermittent corticosteroids for inflammatory or autoimmune disorders within 3 weeks prior to Study Day 1.~* Transfusion-dependent subjects.~* Presence of central nervous system (CNS) lymphoma.~* Histologic transformation.~* Presence of pleural or peritoneal effusion with positive cytology for lymphoma.~* Another primary malignancy requiring active treatment.~* Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions that would compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.~* New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to Study Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low Fiber Diet for Bowel Preparation for Colon Capsule Examination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 and \<75~* Colon study indicated for colo-rectal carcinoma screening~* After colonoscopy for any indication failed due to technical causes~* Patients who decline an indicated colonoscopy~Exclusion Criteria:~* Significant heart failure (NYHA grade III-IV)~* Renal failure (Creatinine \> 1.2 mg/dl)~* Known or suspected intestinal strictures~* Known or suspected mesenteric adhesions~* History suggestive of bowel obstruction~* Vomiting and/or aspirations~* Symptoms of dysphagia~* Pace-maker or AICD implanted~* Known allergy or intolerance to any of the study drugs~* Pregnancy~* Illicit drug abuse or alcoholism~* Inability to provide an informed consent

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Low fiber diet for 5 days prior to procedure
- 2 (Type: ACTIVE_COMPARATOR): regular diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Value of Portable Ultrasound for Dyspneic Patient Support in the Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* Patient consulting in the emergency department for dyspnea~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient cannot read French~* The patient is pregnant, parturient, or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care (Type: ACTIVE_COMPARATOR): Patients randomized to this arm will receive standard care.~Intervention: Standard care.
- Standard care + ultrasound (Type: EXPERIMENTAL): Patients randomized to this arm will receive standard care + pleuropulmonary ultrasound.~Intervention: Standard care + ultrasound

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years of age~* Patient is human immunodeficiency virus (HIV) positive~* Patient has documented Human Immunodeficiency Virus (HIV) RiboNucleic Acid (RNA) \<50 copies/milliliter (mL) for at least 3 months while on a KALETRA based regimen~* Patient has been on a KALETRA based regimen for at least 3 months without a change in background antiretroviral therapy~* Patient has no documentation of HIV RNA \>50 copies/mL for at least 3 months while on the KALETRA based regimen~Exclusion Criteria:~* Patient is or plans to become pregnant, or is nursing a child~* Patient plans to donate eggs or impregnate/donate sperm~* Patient is receiving Stavudine (d4T) as a component of the background antiretroviral therapy~* Patient is currently receiving a second protease inhibitor in addition to KALETRA~* Patient is currently receiving, or has received in the past twelve weeks, treatment for the management of elevated lipids~* Patient has used another experimental HIV-integrase inhibitor~* Patient has a current (active) diagnosis of acute hepatitis due to any cause

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Raltegravir \& Placebo
- 2 (Type: ACTIVE_COMPARATOR): Lopinavir (+) Ritonavir \& Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The characteristics of the treatment history:~  1. No sorafenib treatment history, no sorafenib allergies.~ 2. No chemotherapy, radiotherapy and transcatheter arterial chemoembolization(TACE) treatment history before surgery.~* The characteristics of the tumor:~  1. The pathological results is hepatocellular carcinoma.~ 2. Meet any of the following articles:~     * Pathological prompt microvascular invasion(MVI) class II, and incorporate any of the following:Tumor number\>3,Tumor size\>8cm,Tumor margin is not clear and no complete capsule.~    * With the embolus in Portal vein, hepatic vein or bile duct.~    * Preoperative rupture or invasion the adjacent organs.~    * The positive cut edge.~    * Residual lesions showed by Postoperative digital subtraction angiography(DSA).~    * Alpha fetoprotein(AFP) did not drop to normal range two months after surgery.~* The characteristics of the patients:~  1. The patient age was between 18-75.~ 2. The American Society of Anesthesiologists(ASA）score was I-III.~ 3. No history of esophageal varices and gastrointestinal bleeding.~ 4. The Child-pugh score was A.~ 5. Routine blood test: the leukocyte\>2.5\*10\^9, platelet\> 60\*10\^9.~ 6. The Prothrombin time was prolonged less than 2 second.~ 7. The Eastern Cooperative Oncology Group(ECOG) score was less than 2 points~Exclusion Criteria:~* Sorafenib treatment before surgery.~* Pregnant or lactating women.~* The Child-pugh score was B-C.~* Patients with other malignant tumor.~* Patients with mental illness.~* Patients participated in other clinical trials in last three months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: PLACEBO_COMPARATOR): just follow up after liver resection in HCC patients
- sorafenib (Type: ACTIVE_COMPARATOR): use sorafenib after liver resection in HCC patients
- sorafenib and aspirin (Type: ACTIVE_COMPARATOR): use sorafenib and aspirin after liver resection in HCC patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men or women age ≥18 years~* Histologically or cytologically confirmed NSCLC (Recurrent, locally advanced or metastatic, inoperable NSCLC \[Stage IIIB/IV\]. Patients with Stage IIIB NSCLC must have a cytologically documented pleural effusion.)~* Failed or relapsed after receiving a platinum-containing chemotherapy regimen as first-line therapy for advanced NSCLC~* Measurable disease on computerized tomography (CT) scan~* ECOG Performance Status of 0 or 1~* Expected survival ≥12 weeks~* Provide written informed consent~Exclusion Criteria:~* More than 2 prior chemotherapy regimens~* Progression of disease on prior pemetrexed treatment~* Brain metastases (exception: patients who had a resection and/or completed a course of cranial irradiation, have no worsening CNS symptoms, and have discontinued all corticosteroids for that indication for at least 1 month)~* Serum creatinine ≥2.0mg/dL or creatinine clearance \<45mL/min~* Absolute neutrophil count \<1500/μL or platelets \<100,000/μL~* Any malignancy within 5 years immediately prior to the first dose of study medication (exception: basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix)~* Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol~* Patients who are within 28 days of chemotherapy, radiation therapy, immunotherapy, or investigational medication for NSCLC. Patients must have recovered from all of the side effects of treatment.~* Pregnancy or lactation. Women of childbearing potential and non-vasectomized men must agree to use a barrier method of contraception during treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY.~Inclusion:~* Patients 18 years or older.~* Diagnosed with type 2 diabetes mellitus within the past 30 days or who have been diagnosed and have not begun treatment.~Exclusion:~* Subjects who are \<18 yrs of age.~* Pregnant or breastfeeding.~* Allergic to cinnamon.~* Allergic to metformin.~* Patients taking metformin are excluded from participating, unless they agree to wash out for two weeks prior to entering the study.~* Patients taking Cinnamon as a dietary supplement are excluded from participating, unless they agree to wash out for two weeks prior to entering the study.~* Patients taking any of the following:~  * Daily oral steroids~ * Warfarin~ * Hypoglycemic medication~ * Weight loss medication~ * Digoxin, lithium, phenytoin, \& theophylline (due to narrow therapeutic indices)~* Serum creatinine \>1.5 (this is standard of care that would be measured by PCM upon diagnosis of type 2 diabetes mellitus)~* Initial hemoglobin A1C \>9.5(this is standard of care that would be measured by PCM upon diagnosis of type 2 diabetes mellitus).~* Clinical or laboratory evidence of liver disease.~* Clinical or laboratory evidence of Alcoholism.~* New York Heart Association (NYHA) Class III and IV congestive heart failure.~  * Class III: Cardiac disease resulting in marked limitation of physical activity - less than ordinary activity causes fatigue, palpitation, dyspnea, or angina. Comfortable at rest.~ * Class IV: Cardiac disease resulting in inability to carry on any physical activity without discomfort or symptoms. Symptoms may be present at rest. If any physical activity is undertaken, discomfort or symptoms are increased.~* Patients who are known to have or develop during the study any of the following upon review of their medical record:~  * Celiac disease~ * Insulinoma~ * Cushings Disease~ * Hyperthyroidism~ * Acromegaly~ * Phechromocytoma~ * Addison's Disease~ * Galactosemia~ * Glycogen storage disease~ * Hereditary fructose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): oral extended-release Metformin 1000 mg once a day for 90 days
- Cinnamon Bark (Type: EXPERIMENTAL): Cinnamon Bark 1000 mg once a day for 90 days
- Cinnulin PF (Type: EXPERIMENTAL): Cinnulin PF 500 mg once a day for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed metastatic melanoma~  * Stage IV disease~ * Progressive disease~ * No known standard therapy that is potentially curative or proven capable of extending life expectancy exists~* Planning to undergo chemotherapy with paclitaxel and carboplatin OR temozolomide alone for progressive disease~* Measurable disease as defined by RECIST criteria~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 3 months~* ANC ≥ 1,500/mL~* Platelet count ≥ 100,000/mL~* Hemoglobin ≥ 9 g/dL~* Creatinine ≤ 2.5 x upper limit of normal (ULN)~* AST ≤ 3 x ULN~* Alkaline phosphatase ≤ 3.0 x ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 1 month after completion of study therapy~* No uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Active infection~ * NYHA class III or IV congestive heart failure~* No history of other malignancy within the past 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix~* Willing to provide research blood samples~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* At least 4 weeks since prior radiotherapy~* At least 4 weeks since prior chemotherapy (patients who received chemotherapy in the metastatic setting)~  * No prior chemotherapy treatment with agents similar to study drugs~* No prior chemotherapy in the metastatic setting (for chemo-naive patients)~* No concurrent enrollment in a different clinical study in which investigational procedures or agents are being used~* No other concurrent investigational agents~* No other concurrent chemotherapy or radiotherapy, including palliative radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- PC (previously treated) (Type: EXPERIMENTAL): Previously chemotherapy treated cohorts: Paclitaxel and Carboplatin (PC)
- PC (chemo naive) (Type: EXPERIMENTAL): Chemotherapy-naive cohorts: Paclitaxel and Carboplatin (PC)
- TMZ (previously treated) (Type: EXPERIMENTAL): Previously chemotherapy treated cohorts: Temozolomide (TMZ)
- TMZ (chemo naive) (Type: EXPERIMENTAL): Chemotherapy-naive cohorts: Temozolomide (TMZ)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial Comparing Slow-freezing to Vitrification of Oocytes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 14 or more oocytes at ovum pick up~* age \< 38~* bmi \< 30~Exclusion Criteria:~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): slow-freeze
- 2 (Type: ACTIVE_COMPARATOR): vitrification

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who were diagnosed with primary breast cancer by core biopsy~2. Patients who have been identified as HER2 negative in the tissue obtained through core needle biopsy and have confirmed the positive / negative status of ER (Estrogen receptor) and Progesterone receptor (PR)~   * HER2 positive is defined as IHC 3+ or FISH +~3. Patinets whose TNM stage confirmed by CT or MRI (T2-T3, anyN, M0 or T1-3, N1-3, M0)~Exclusion criteria:~1. Patients who have distant metastasis~2. Patients who have cystitis or urinary obstruction~3. Patients who have history of thromboembolism or coagulation disorder~4. Patients who have Interstitial lung disease ans liver cirrhosis ( \> Child-Pugh class B)~5. Patients who have Insulin-Dependent Type II diabete mellitus

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nanoxel M (Type: EXPERIMENTAL): AC(Doxorubicin, Cyclophosphamide) followed by Nanoxel M
- Taxotere (Type: ACTIVE_COMPARATOR): AC(Doxorubicin, Cyclophosphamide) followed by Taxotere

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues